The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Jul 2014 09:37

Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation.African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy.Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold recommendation. Investec raises target price from 1630p to 1760p and keeps a hold recommendation.APR Energy: Investec places its target price (prev.: 880p) under review, while keeping a hold recommendation.Barclays: Numis upgrades from add to buy with a target price of 280p.Brammer: Investec cuts target price from 450p to 435p, while upgrading from hold to buy.BSkyB: Westhouse Securities upgrades from neutral to add with a target price of 985p.BTG: Jefferies ups target price from 525p to 760p upgrading from hold to buy.Compass Group: Deutsche Bank raises target price from 1025p to 1105p and retains a buy recommendation.Daily Mail & General Trust: Credit Suisse reinstates with a target price of 1040p and an outperform rating.Drax Group: Goldman Sachs cuts target price from 1098p to 1052p retaining a strong buy recommendation.Gem Diamonds: FinnCap ups target price from 211p to 261p and maintains a buy recommendation. Westhouse Securities ups target price from 220p to 235p and reiterates its buy recommendation.GKN: Numis upgrades from add to buy with a target price of 435p.GlaxoSmithKline: Berenberg reduces target price from 1740p to 1520p, while leaving its hold recommendation unchanged.Hiscox: Deutsche Bank cuts target price from 658p to 646p staying with its sell recommendation. Canaccord Genuity shifts target price from 705p to 710p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank reduces target price from 640p to 593p and reiterates a hold recommendation.Hutchison China Meditech: Panmure Gordon raises target price from 950p to 1200p keeping a buy recommendation.Informa: Canaccord Genuity cuts target price from 535p to 515p staying with its hold recommendation.Jardine Lloyd Thompson: Numis cuts target price from 1190p to 1120p downgrading from add to hold.Ladbrokers: Deutsche Bank lowers target price from 177p to 165p and keeps a buy recommendation.Lancashire Holdings: Berenberg reduces target price from 720p to 666p keeping a hold recommendation.Pace: Numis reduces target price from 420p to 360p and reiterates a hold recommendation.Petra Diamonds: Beaufort upgrades to buy. Numis ups target price from 220p to 240p, while downgrading from buy to add.Provident Financial: Espirito Santo raises target price from 1808p to 2012p and retains a neutral rating.Reckitt Benckiser: Credit Suisse raises target price from 5200p to 5500p and maintains an outperform rating. Numis downgrades from add to hold with a target price of 5600p.Sinclair IS Pharma: Jefferies lowers target price from 50p to 45p staying with its buy recommendation.Spectris: Goldman Sachs reduces target price from 3050p to 2770p and keeps its strong buy recommendation. Credit Suisse reduces target price from 2560p to 2370p and leaves its outperform rating unaltered. Canaccord Genuity reduces target price from 2700p to 2400p and downgrades from buy to hold.Sweett Group: N+1 Singer cuts target price from 61p to 45p retaining a buy recommendation.Tesco: Shore Capital upgrades from sell to hold.Treatt: Investec moves target price from 150p to 160p reiterating a hold recommendation.Tullett Prebon: Numis places both its target price (prev.: 299p) and its reduce rating under review. Liberum Capital places its target price (prev.: 240p) under review with a sell recommendation. Canaccord Genuity places both its target price and recommendation under review.William Hill: Deutsche Bank cuts target price from 435p to 415p leaving its buy recommendation unchanged.Zoopla Property: Credit Suisse initiates with a target price of 290p and an outperform rating.7Digital: Investec initiates with a target price of 37p and a buy recommendation.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.